Here are five recent news updates on gastroenterology and endoscopy companies.
Analysts with RBC Capital increased their price target of Boston Scientific to $20.
Ferring Pharmaceuticals and Institut Pasteur, a non-profit biomedical research center, are collaborating on the development novel drug development for the treatment of inflammatory bowel disease, according to a PMLive report.
EndoChoice named Scott Huennekens its chairman of the board.
http://www.endochoice.com/site/downloads/PR-15-009-1%20Scott%20Huennekens%20COB.pdf
Olympus warned European hospitals of infection risk linked to its TJF-Q180V duodenoscope approximately two years ago, but a similar warning was not released in the United States until recently.
Ritter Pharmaceuticals named Gerald T. Proehl the seventh member of its board of directors.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.